A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
Diyuan Xue, Benjamin Moon, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang‐Xin Fu, Hua Peng
Abstract
, T cells was essential for maximal effectiveness. Pro-IL-12 improved the efficacy of both immune checkpoint blockade and targeted therapy when used in combination. Therefore, our study demonstrated that pro-IL-12 could rejuvenate TILs, which then combined with current treatment modalities while limiting adverse effects for treating established tumors.
Topics & Concepts
Cancer researchCD8Cytotoxic T cellToxicityBlockadeMedicineImmunotherapyImmunologyInterleukinImmune systemTumor-infiltrating lymphocytesReceptorBiologyCytokineInternal medicineIn vitroBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses